Tag: Caplacizumab

Cablivi (caplacizumab), a significant advancement in treating a rare blood-clotting disorder, was developed from a unique discovery in camel blood, leading to the creation of its innovative "nanobody" technology. Today, the global pharmaceutical company Sanofi is responsible for the manufacture and commercialization of caplacizumab.

Without treatment, thrombotic thrombocytopenic purpura (TTP) has a mortality rate exceeding 90% [1.4.7]. While modern treatments have dramatically improved survival, a key question remains for many: **Is rituximab FDA approved for TTP?** The answer is no, but its role is critical [1.2.1, 1.3.1].